Friday, December 12, 2025

PharmaTher To Raise $10.0 Million Via Institutional Investor Financing

PharmaTher Holdings (CSE: PHRM) this morning indicated that the company has secured a financing with institutional investors. The firm will be raising C$10.0 million via a financing conducted exclusively by H.C. Wainwright.

The financing will see the company sell a total of 15.6 million units of the company price at $0.64 per each, with each unit containing one common share and one common share purchase warrant. Each warrant, priced at $0.80 per share, is valid for a period of five years from the date of issuance.

Proceeds from the financing are to be used for the development of the firms microneedle patch, its ketamine product, and general working capital.

The financing is currently slated to close September 28, 2021.

PharmaTher Holdings last traded at $0.80 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. PharmaTher Holdings is a former client of The Deep Dive. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Canada Has So Few Projects That Can Be Built Before 2030 | Dan Wilton – First Mining

Guanajuato Silver: Q3 Results Overshadowed By Silver Ripping

I Went to See the Highest Grade Silver on Earth | Nord Precious Metals

Recommended

Steadright Locks Up Goundafa Polymetallic Mine Under Binding MOU

Emerita Resources Awards Contract For Pre-Feasibility Study On Iberian Belt West Project

Related News

Pharmather Acquires Exclusive License For Ketamine Treatment Against Parkinson’s Disease

Pharmather Inc (CSE: PHRM) this morning announced that it has entered into an exclusive licensing...

Thursday, October 15, 2020, 09:02:27 AM

PharmaTher: Maxim Initiates Coverage With US$1.50 Price Target

PharmaTher Holdings (CSE: PHRM) had its first initiation report that came out on June 28th....

Wednesday, June 30, 2021, 02:38:00 PM

PharmaTher Files With FDA For Pre-IND Meeting On Use Of Ketamine In Treatment Of Parkinson’s Disease

PharmaTher Inc (CSE: PHRM) this morning announced that it has filed a pre-investigational new drug...

Tuesday, December 8, 2020, 09:08:04 AM

PharmaTher Submits For Phase 2 Clinical Trial With FDA

PharmaTher Holdings (CSE: PHRM) is looked to complete a phase two clinical trial. The company...

Tuesday, April 20, 2021, 07:38:21 AM

PharmaTher Applies For Pre-IND Meeting With US FDA For Ketabet

PharmaTher Holdings (CSE: PHRM) this morning announced that it continues to push forward with the...

Tuesday, June 15, 2021, 08:14:25 AM